Amerikanische Gesellschaft für Hirudotherapie

Complement C3b contributes to-induced platelet aggregation in human whole blood

Research article published in Frontiers in immunology (2022)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportAntimikrobielle ResistenzSpeichel-PharmakologieLandsem A et al. · Frontiers in immunology, 2022

Abstract

INTRODUCTION: Platelets have essential functions as first responders in the immune response to pathogens. Activation and aggregation of platelets in bacterial infections can lead to life-threatening conditions such as arterial thromboembolism or sepsis-associated coagulopathy. METHODS: In this study, we investigated the role of complement in Escherichia coli (E. coli)-induced platelet aggregation in human whole blood, using Multiplate® aggregometry, flow cytometry, and confocal microscopy. RESULTS AND DISCUSSION: We found that compstatin, which inhibits the cleavage of complement component C3 to its components C3a and C3b, reduced the E. coli-induced platelet aggregation by 42%-76% (p = 0.0417). This C3-dependent aggregation was not C3a-mediated as neither inhibition of C3a using a blocking antibody or a C3a receptor antagonist, nor the addition of purified C3a had any effects. In contrast, a C3b-blocking antibody significantly reduced the E. coli-induced platelet aggregation by 67% (p = 0.0133). We could not detect opsonized C3b on platelets, indicating that the effect of C3 was not dependent on C3b-fragment deposition on platelets. Indeed, inhibition of glycoprotein IIb/IIIa (GPIIb/IIIa) and complement receptor 1 (CR1) showed that these receptors were involved in platelet aggregation. Furthermore, aggregation was more pronounced in hirudin whole blood than in hirudin platelet-rich plasma, indicating that E. coli-induced platelet aggregation involved other blood cells. In conclusion, the E. coli-induced platelet aggregation in human whole blood is partly C3b-dependent, and GPIIb/IIIa and CR1 are also involved in this process.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsHumansBlood PlateletsComplement C3bEscherichia coliHirudinsPlatelet AggregationPlatelet Glycoprotein GPIIb-IIIa ComplexIn Vitro TechniquesReceptors, Complement 3b

Zusammenfassung

Platelets have essential functions as first responders in the immune response to pathogens.

Warum dies für die Hirudotherapie relevant ist

This study investigated the role of complement C3b in Escherichia coli–induced platelet aggregation in human whole blood using Multiplate aggregometry, flow cytometry, and confocal microscopy. Compstatin and a C3b-blocking antibody reduced E. coli–induced aggregation, and aggregation was more pronounced in hirudin whole blood than in hirudin platelet-rich plasma

Zitation

Complement C3b contributes to-induced platelet aggregation in human whole blood

Landsem A et al. · Frontiers in immunology, 2022

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.